Catalyst Event
ABL Bio Inc (298380) · Earnings Release
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/8/2026, 12:00:00 AM
Announced Q1 2026 earnings on May 8, 2026, with revenue of KRW 13.1 billion, primarily from technology transfer fees. The company reported holding approximately KRW 190 billion in cash and cash equivalents.
Korean Translation
2026년 5월 8일, 2026년 1분기 실적을 발표함. 매출액은 131억 원으로 주로 기술이전료 수익으로 구성되었으며, 약 1,900억 원의 현금성 자산을 보유하고 있다고 밝힘.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM